[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542686":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":32,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":32,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":32,"enrollmentInfo":69,"targetDuration":32,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":32,"overallStatus":41,"whyStopped":32,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo capsules","PLACEBO_COMPARATOR","Placebo capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD1\u002FPD-L1 will be intravenously infused every three weeks for 24 weeks.",[13],"Procedure: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"FMT capsules","EXPERIMENTAL","FMT capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD1\u002FPD-L1 will be intravenously infused every three weeks for 24 weeks.",[19],"Procedure: Fecal Microbiota Transplantation Capsules",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Fecal Microbiota Transplantation Capsules","FMT Capsules in Combination with Chemotherapy and Anti-PD1\u002FPD-L1 Therapy",[15],[27],"FMT Capsules",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Mainly composed of starch, the appearance, shape, color, and size are exactly the same as FMT capsules",[9],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Xiangyu Kong, associate professor","CONTACT","13564644397","xiangyukong185@hotmail.com",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Shanghai","Shanghai Municipality","200433","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":37,"phoneExt":32,"email":38},"Xiangyu Kong, Associate Professor",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Xiangyu Kong","Principle Investigator","100542686","fecal-microbiota-transplantation-fmt-in-patients-with-advanced-gastric-cancer-100542686",false,"NCT06346093","Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer","A Prospective, Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\nVoluntarily participate in this study and provide written informed consent. Age ≥ 18 years , male or female. Pathological confirmed locally advanced, unresectable or metastatic gastric adenocarcinoma, esophagogastric junction adenocarcinoma.\n\nAble and willing to provide tumor tissue. At least one measurable extracranial target lesion according to iRECIST. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. Life expectancy ≥3 months.\n\nExclusion Criteria:\n\nPresence of absolute contra-indications to FMT administration:Toxic megacolon;Inflammatory bowel disease;Anatomic contra-indications to colonoscopy;Colectomy Patient is currently participating and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of this study intervention.\n\nCurrently under any form of systemic antibiotics. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy two weeks prior to trial treatment. Patients receiving systemic steroids at physiologic doses are permitted to enroll assuming steroid dose is not above the acceptable threshold (\\> 10 mg prednisone daily or equivalent).\n\nSevere anaphylactic reaction to any food (food allergies). Had a severe hypersensitivity reaction to propofol. Has serious concomitant illnesses. The eligibility can be granted by the treating investigator on individual bases.\n\nHas HIV infection or AIDS-related illness. Has active infection of HAV, HBV or HCV. Patients with a history of Hepatitis B\u002FC infection who have received anti-viral therapy and are disease free may be considered for enrollment after discussion with Principal Investigator.\n\nPatient has received a live vaccine within 4 weeks prior to the first dose of treatment. Seasonal influenza vaccines or COVID-19 vaccines for injection are generally inactivated virus vaccines and are allowed.\n\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\nFemales who are pregnant or breastfeeding. Active central nervous system (CNS) metastases and\u002For leptomeningeal involvement","ALL","18 Years",{"count":70,"type":71},124,"ESTIMATED","INTERVENTIONAL",[74],"NA","This study is a randomized, double-blind and placebo-controlled study. The purpose of this study is to evaluate the efficacy and safety of FMT capsules combined with chemotherapy and anti-PD1\u002FPDL1 therapy in the advanced gastric cancer.",[77],"Advanced Gastric Cancer","2025-06-04",{"date":80,"type":81},"2025-06-10","ACTUAL",{"date":83,"type":81},"2024-04-02",{"date":85,"type":71},"2030-06-30",{"name":5,"class":6},1]